Plate Nº 80 · recorded November 14, 2026
Biology & EvolutionReported finding
Fruit Fly Sleep Protein Yields Peptides That Kill Drug-Resistant Bacteria
Peptides from the fruit fly sleep protein Nemuri inhibit drug-resistant bacteria in lab tests by clumping ribosomes, blocking protein synthesis without membrane damage.
By Marcus Bennett3 min read673 words
In brief
- Peptides derived from the fruit fly sleep protein Nemuri inhibit drug-resistant bacteria in laboratory tests
- In E. coli and S. aureus, the peptides kill bacteria at concentrations close to those that inhibit growth
- The peptides clump ribosome-rich regions, reducing ribosome mobility and suppressing protein synthesis
- The study, published in Nature Communications in 2026, reports low toxicity to cultured insect and mammalian cells
- Animal-model testing of efficacy and safety is still required before any therapeutic potential can be judged
Peptides derived from Nemuri — a sleep-inducing protein in the fruit fly Drosophila melanogaster — can inhibit the growth of drug-resistant bacteria in laboratory tests, according to researchers at the University of Tsukuba and collaborating institutions. The team published its results in Nature Communications in 2026.
The findings arrive as antibiotic-resistant bacteria continue to pose a global health threat. Clinicians need antimicrobial agents that act through mechanisms distinct from those of existing antibiotics, and the Nemuri-derived peptides appear to fit that requirement.
For practitioners, the significance is straightforward: these are new molecules with a new target, and they work against clinically important drug-resistant strains.
What did the researchers find?
The team identified several short peptides derived from Nemuri, a protein previously discovered in Drosophila melanogaster. They named these fragments Nemuri peptides and tested them against a wide range of microorganisms, including clinically important drug-resistant bacteria. The peptides inhibited growth across that panel.
In two workhorse bacterial species — Escherichia coli and Staphylococcus aureus — the peptides went beyond growth inhibition. They killed bacteria at concentrations close to those required merely to stop growth, meaning the gap between a static and a bactericidal effect is small.
In plain terms: at roughly the dose that slows the bacteria down, the peptides start killing them.
How do the peptides work?
The mechanism is the study's central contribution. The researchers showed that Nemuri peptides enter bacterial cells and accumulate in regions rich in ribosomes — the molecular machines that build proteins — and RNA.
Notably, the peptides did not substantially disrupt the bacterial membrane at antimicrobial concentrations under the conditions tested. Most conventional antibiotics and many known antimicrobial peptides attack the membrane, the ribosome's active site, or specific enzymes. These peptides do something different.
They interact broadly with RNA molecules and ribosomal surfaces, triggering a condensation-like remodeling of ribosome-rich regions. Think of it as clumping the cell's protein factories together. This remodeling:
- Reduces ribosomal mobility inside the cell
- Suppresses global protein synthesis across the bacterium
- Avoids the membrane damage that many existing antimicrobial peptides cause
The authors conclude that Nemuri peptides inhibit bacterial protein synthesis through changes in the physical organization and dynamic properties of ribosome-rich regions — a mechanism distinct from how current antibiotics operate.
The approach worked without harming the researchers' own test cells: the peptides showed low toxicity toward cultured insect and mammalian cells.
Why does a sleep protein fight bacteria?
The Nemuri protein itself was previously discovered in Drosophila melanogaster, where it induces sleep. The new study repurposes fragments of that protein as antimicrobial candidates. The connection between sleep regulation and immune defense in insects is an established theme in fly biology, and this work extends it to a concrete molecular mechanism.
For researchers in the field, the takeaway is that sleep-associated proteins can be mined for antimicrobial peptides with unusual intracellular targets.
How preliminary are these results?
Caution is warranted. Every result so far comes from laboratory tests: cultured bacteria, cultured insect cells, and cultured mammalian cells. No animal or human data exist yet.
The authors themselves flag the gap. They state that further studies, including evaluations of efficacy and safety in animal models of bacterial infection, are required before anyone can judge whether Nemuri peptides can become real drugs.
Several questions remain open:
- Whether the peptides survive in a living animal's body and reach infected tissues
- Whether the ribosome-condensation mechanism holds up in vivo, not just in culture
- What dose levels are safe and effective in infection models
- Whether bacteria can readily develop resistance to this mechanism
The study positions Nemuri peptides as a starting point for drug development against drug-resistant bacteria — not as a treatment.
Publication details
Suguru Nishinami et al., "Antimicrobial peptides derived from Nemuri induce ribosomal condensation to inhibit translation," Nature Communications (2026). DOI: 10.1038/s41467-026-78960-5.
The research was provided by the University of Tsukuba.
A fruit fly's sleep protein, repurposed in a dish, kills drug-resistant bacteria by gumming up their protein factories.
via phys.org/rss-feed/ (Source)
More from Marcus Bennett
Show full bio
News editor covering regulation, policy and their impact on general science news at SciBeat.
408 articles
Nearby plates
- Scientists identify first PLP-dependent tRNA-modifying enzyme
- Two Protein Plugs Help Superbug P. aeruginosa Block Antibiotics
- Three phage proteins lock bacterial transporter MurJ in place
- Johns Hopkins Team Finds the Docking Point a Gut Toxin Uses to Attack the Colon
- Phage enzyme cut triggers bacterial suicide defense, study finds